Clinical Trials Sponsored by Nitto+Denko+Corporation

Total 7 results

Nitto Denko Corporation

Completed

JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

Idiopathic Pulmonary Fibrosis

United States, Germany, Japan, United Kingdom
Nitto Denko Corporation

Completed

Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male Volunteers

Influenza

Japan
Bristol-Myers Squibb
Nitto Denko Corporation

Completed

A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body

Fibrosis
Bristol-Myers Squibb
Nitto Denko Corporation

Completed

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)

Bulgaria, United States
Bristol-Myers Squibb
Nitto Denko Corporation

Completed

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

Healthy

United States
RenJi Hospital
Nitto Denko Corporation; Giant Med-Pharma Services Inc.

Unknown

Lidocaine Patches for Attenuating the Pain of Venipuncture Intravenous Cannulation

We Focus on the Pain of Venipuncture and Intravenous Cannulation

China
University of California, San Diego
Nitto Denko Asia Technical Centre (NAT)

Completed

PSG Validation Study of Zensorium Biosensing Wearable Device

Sleep Wake Disorders | Healthy

United States

3

Subscribe